News >

MCL Treatment Paradigm Expands With Novel Combos

Brandon Scalea
Published: Wednesday, May 01, 2019

Timothy Fenske, MD, MS

Timothy Fenske, MD, MS

Beyond effective BTK inhibitors, novel combinations with venetoclax (Venclexta), PI3K inhibitors, and proteasome inhibitors all have the potential to further improve survival in patients with relapsed/refractory mantle cell lymphoma (MCL), said Timothy Fenske, MD, MS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication